Next Article in Journal
Is Kinesio Taping Effective for Sport Performance and Ankle Function of Athletes with Chronic Ankle Instability (CAI)? A Systematic Review and Meta-Analysis
Next Article in Special Issue
Approach to Thrombophilia in Pregnancy—A Narrative Review
Previous Article in Journal
Photobiomodulation Therapy in the Treatment of Oral Mucositis—A Case Report
Previous Article in Special Issue
The Impact of SARS-CoV-2 Infection on Premature Birth—Our Experience as COVID Center
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 58
Issue 5
10.3390/medicina58050619
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Pregnancy Outcomes in a Cohort of Patients Who Underwent Double-J Ureteric Stenting—A Single Center Experience

by
Viorel Dragos Radu
1,2,
Ingrid-Andrada Vasilache
3,*,
Radu-Cristian Costache
1,2,
Ioana-Sadiye Scripcariu
3,
Dragos Nemescu
3,
Alexandru Carauleanu
3,
Valentin Nechifor
3,
Veaceslav Groza
2,
Pavel Onofrei
4,
Lucian Boiculese
5 and
Demetra Socolov
3
1
Urology Department, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania
2
Urology Department, ‘C.I. Parhon’ University Hospital, 700115 Iasi, Romania
3
Department of Obstetrics and Gynecology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania
4
Morphofunctional Sciences II Department, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania
5
Medical Informatics and Biostatistics Department, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania
*
Author to whom correspondence should be addressed.
Medicina 2022, 58(5), 619; https://doi.org/10.3390/medicina58050619
Submission received: 23 March 2022 / Revised: 23 April 2022 / Accepted: 27 April 2022 / Published: 29 April 2022
(This article belongs to the Special Issue Diagnosis, Evaluation, and Management of Diseases during Pregnancy)
Versions Notes

Abstract

:
Background and Objectives: Minimally invasive procedures, such as double-J ureteric stenting, could be a promising therapeutic alternative to conservative management of obstructive urinary tract pathology. We aimed to evaluate the safety and effectiveness of double-J ureteric stenting in pregnant women with ureterohydronephrosis or urolithiasis, along with their infectious complications, and to assess the pregnancy outcomes of this cohort of patients in comparison with a control group. Materials and Methods: This observational retrospective study included 52 pregnant patients who underwent double-J ureteric stenting for urologic disorders in the Urology Department of ‘C.I. Parhon’ University Hospital, and who were followed up at a tertiary maternity hospital- ‘Cuza-Voda’, Iasi, Romania. The control group (63 patients) was randomly selected from the patient’s cohort who gave birth in the same time frame at the maternity hospital, without urinary pathology. Clinical, sonographic, and laboratory variables were examined. Descriptive statistics, non-parametric tests, and a one-to-one propensity score-matched analysis were used to analyze our data. Results: The univariate analysis indicated a significant statistical difference between the control group and the interventional group regarding maternal age (p = 0.018), previous maternal history of renal colic (p = 0.005) or nephrolithiasis (p = 0.002). After applying the propensity score-matched analysis, cesarean delivery rates (p < 0.001), preterm labour (p = 0.039), premature rupture of membranes (p = 0.026), preterm birth rates (p = 0.002), and post-partum UTI rates (p = 0.012) were significantly different between the control group and the matched treatment group. Ureterohydronephrosis, whether simple (n = 37; 71.2%) or infected (n = 13; 25%), was the main indication for double-J ureteric stenting. Complications such as pain (n = 21; 40.3%), stent migration (n = 3; 5.76%) or encrustation (n = 2; 3.84%), as well as reflux pyelonephritis (n = 2; 3.84%) and gross hematuria (n = 1; 1.92%) were recorded during follow-up. Conclusions: Our results show that double-J stenting is a safe and effective treatment option for pregnant patients with obstructive urological disorders.

1. Introduction

Ureterohydronephrosis (UHN) is a common maternal adaptation to pregnancy, affecting more than 40% of pregnancies, and is more prevalent in the third trimester [1]. The anatomical changes of the pyelocaliceal system are predominantly encountered in the right side, due to the anatomical relationship of the ureter with iliac and ovarian vessels [2]. Ureterohydronephrosis, along with hormonal and immune changes, predispose pregnant women to infectious complications that range between simple urinary tract infections to urosepsis [3].
Urolithiasis (UL) development during pregnancy is supported by systemic, nephrological and mechanical changes [4], and is associated with important adverse pregnancy outcomes such as preterm birth, preeclampsia or gestational hypertension [5]. If left untreated, obstructive uropathy can lead to urosepsis and renal failure, which could ultimately result in preterm birth, abruptio placentae, stillbirth, or maternal mortality [6,7,8].
Prenatal management of urinary tract pathology is based on correct diagnosis and individualized treatment. Ultrasonography (USG), magnetic resonance imaging (MRI), complete blood count (CBC), inflammatory markers (C-reactive protein—CRP), renal function tests, urinary analysis, and urine culture are useful diagnostic tools for detection of urinary tract disorders during pregnancy [5,9,10].
Individualized treatment of urinary pathology during pregnancy consists of a conservative (hydration, analgesia, and/or antibiotic treatment) and a surgical approach. The surgical approach is mainly represented by ureteric stent insertion, percutaneous nephrostomy (PCN) and ureteroscopic extraction of the calculus [11,12,13].
Ureteric stenting is a minimally invasive procedure with a good safety profile during pregnancy that can be used for drainage of the obstructed and/or infected urinary system in patients with symptoms refractory to conservative approaches and/or changes in renal function, pain visual analogue score, obstruction or hydronephrosis grading [14]. The procedure can be easily performed in the lithotomy position, without general anaesthesia [15].
The aim of this study was to evaluate the safety and effectiveness of double-J ureteric stenting in pregnant women with ureterohydronephrosis and renal obstruction due to calculi or physiological obstruction, along with their infectious complications, and to assess the pregnancy outcomes of this cohort of patients in comparison with a control group.

2. Materials and Methods

We conducted an observational retrospective study of all pregnant patients who underwent double-J ureteric stenting for urologic disorders (ureterohydronephrosis, urolithiasis, and their infectious complications) in the Urology Department of ‘C.I. Parhon’ University Hospital, Iasi, Romania, between January 2014 and December 2020. All patients were followed up at a tertiary maternity hospital- ‘Cuza-Voda’, Iasi, Romania. The control group was randomly selected from the patient’s cohort who gave birth in the same time frame at the maternity hospital, without urinary tract pathology.
Ethical approval for this study was obtained from the Institutional Ethics Committees of ‘Cuza-Voda’ Maternity Hospital (No. 2871/05.03.2022) and ‘C.I. Parhon’ University Hospital (No. 1808/04.03.2022). Informed consent was obtained from all participants included in the study. All methods were carried out in accordance with relevant guidelines and regulations.
Medical records of patients were systematically reviewed and data obtained. Exclusion criteria comprised patients who had multiple pregnancies, ectopic pregnancies, first and second trimester abortions, fetal intrauterine demise, fetuses with chromosomal or structural abnormalities, intrauterine infection, incomplete medical records, incorrect/lack of first trimester sonographic pregnancy dating or who were unable to offer informed consent due to various reasons (age less than 18 years old, intellectual deficits, psychiatric disorders, etc.).
A total of 284 pregnant women with urological disorders were admitted at ‘C.I. Parhon’ University Hospital during our study period. Pregnant patients who underwent double-J ureteric stenting were evaluated, and 52 patients were included in our study. The following variables were recorded: demographic data, the patient’s medical history, renal clinical manifestations (febrile syndrome and renal colic) laboratory parameters (CBC, CRP, urinalysis and urine culture), indications for double-J ureteric stenting, duration of the procedure and hospitalization, associated medical treatment, type of complications, and pregnancy outcomes (type of birth, newborn’s gender, Apgar score, preterm labour, premature rupture of membranes, preterm birth, fetal growth restriction, preeclampsia, neonatal intensive care unit (NICU) admission, fetal death, and post-partum UTI). The Apgar score, developed by Dr. Virginia Apgar, was used to assess the status of infants after delivery [16]. It comprises 5 components: (1) color; (2) heart rate; (3) reflexes; (4) muscle tone; and (5) respiration [17]. Each of these components is given a score of 0, 1, or 2. An Apgar score less than 7 indicated the need for special neonatal care, while a score between 7 and 10 was considered reassuring.
All pregnancies were dated by an experienced obstetrician with an early ultrasound scan using an E8/E10 (General Electric Healthcare, Zipf, Austria) scanner with a 4.8 MHz transabdominal probe (GE Medical Systems, Milwaukee, WI) between 10 + 0 to 13 + 6 weeks to determine gestational age by measuring the crown-rump length (CRL) [18].
Ultrasound evaluation was also performed by experienced urologists for diagnostic purposes using Siemens ACUSON ×300 or ACUSON REDWOOD (Siemens Healthcare, Erlangen, Germany, gmbH) scanners, with a 3.5 MHz transabdominal probe. At ultrasound evaluation, we could only assess calculi in the pyelocaliceal system, lumbar and pelvic ureter. The patients presenting with UHN without an ultrasound objectification of a calculi were considered as no-lithiasis patients.
UHN grading, adapted after the Society for Fetal Urology (SFU) system, was considered as follows: (a) grade I: minimal changes in urinary stasis; (b) grade II: slight dilation of the renal pelvis involving major calyces; (c) grade III: moderate dilation of the renal pelvis involving major and minor calyces; (d) stage IV: severe dilation with compression on the renal parenchyma [19,20].
In the presence or absence of cystitis symptoms, flank pain, nausea/vomiting, temperature (>38 °C), and/or costovertebral angle tenderness were used as diagnostic criteria for acute pyelonephritis [21] More than 105 colony-forming units (CFU)/mL was considered a positive urine culture.
Urosepsis was diagnosed in patients meeting two or more of the following criteria according to the quick sepsis-related organ failure assessment (qSOFA): (1) respiratory rate of ≥22 breaths/min; (2) altered consciousness (Glasgow Coma Scale score of <13); (3) systolic blood pressure of ≤100 mmHg [22].
The ureter was stented under local anaesthesia, using pregnancy-approved antibiotic prophylaxis. The procedure was conducted using an Olympus rigid cystoscope, 21CH. A 6, 7 or 8CH, 26, 28 cm length, JJ ureteric stent (MEDpro Medical B.V., Fernendal, The Netherlands) was inserted retrogradely over a guidewire. The ureteric stent’s location was confirmed by observing the stent markings and distal coiling, as well as intraoperative sonographic stent placement inside the pyelocaliceal system. During the procedure, no fluoroscopy was employed.
When the symptomatology subsided or the urosepsis cleared, the patients were discharged. All recommended antibiotic regimens followed the European Association of Urology guidelines [23].
Statistical analysis was performed using SPSS software (version 28.0.1, IBM Corp, Armonk, NY, USA). Each variable was evaluated with chi-squared and Fisher’s exact tests for categorical variables, and T-tests for continuous variables. One-to-one propensity score-matched analysis was performed using Stata SE (version 15, StataCorp LLC), considering demographic characteristics as treatment independent variables, and comparing pregnancy outcomes (type of birth, preterm labour, premature rupture of membranes, preterm birth, neonatal intensive care unit admission rates, and post-partum UTI rates) between the control group (without double-J stent) and treatment group (with double-J stent). A p value less than 0.05 was considered statistically significant.

3. Results

A total of 52 pregnant patients who underwent double-J ureteric stenting were included in our study. A group of 63 patients, who gave birth at ‘Cuza Voda’ Hospital, without urological illnesses and interventions during pregnancy served as our control group. The demographic characteristics, comorbidities, and pregnancy outcomes of cases and controls are presented in Table 1.
Our data indicated a significant statistical difference between the control group and the interventional group regarding maternal age (p = 0.018), previous maternal history of renal colic (p = 0.005) or nephrolithiasis (p = 0.002), type of birth (p < 0.001), newborn’s Apgar score at 5 min (p = 0.007), preterm labour rates (p = 0.03), premature rupture of membranes (p = 0.006), preterm birth (p = 0.002), neonatal intensive care unit (NICU) admission rates (p = 0.03), and post-partum UTI rates (p < 0.001).
After applying the one-to-one propensity score-matched analysis, only cesarean delivery rates (p < 0.001), preterm labour (p = 0.039), premature rupture of membranes (p = 0.026), preterm birth rates (p = 0.002), and post-partum UTI rates (p = 0.012) were significantly different between the control group and the matched treatment group (Table 2).
The most frequent pathogens responsible for post-partum UTI were Escherichia coli (interventional vs. control groups, 3:1 cases), Klebsiella spp. (interventional vs. control groups, 3:1 cases), Enterococcus spp. (interventional vs. control groups, 3:0 cases), followed by Enterobacter spp. (interventional vs. control groups, 1:0 cases) and Staphylococcus spp. (interventional vs. control groups, 1:0 cases). These UTI were treated with Amoxicillin-clavulanic acid 1 g b.i.d or Cefuroxime 1.5 g b.i.d in the post-partum period for 10–14 days.
A total of 52 pregnant patients underwent double-J ureteric stenting in the Urology Department. The mean gestational age at the moment of the procedure was 23.21 ± 7.11 weeks (Table 3). The majority of the procedures were performed in the second trimester (n = 29, 55.8%), and only five procedures were performed in the first trimester of pregnancy.
The mean values and standard deviations (SDs) of pre-procedural leukocytosis and serum CRP were 15,345.23 ± 2340.4/mm3 and 123.32 ± 46 mg/L, respectively. We observed a significant reduction in the post-procedural leukocytosis (8650.8 ± 1890.3/mm3), but we did not evaluate the post-procedural CRP levels due to a slower resolution of the inflammatory syndrome.
The main pathogens that determined urinary tract infection were Escherichia coli (n = 19; 36.5%), Klebsiella spp. (n = 5; 9.61%), Enterococcus spp. (n = 4; 7.6%), followed by Serratia spp. (n = 2; 3.8%) and Staphylococcus spp. (n = 1; 1.92%). Only 4 cases (7.6%) had UTIs resulting from multidrug resistant Escherichia coli, and all of them developed a septic condition.
Antibioprophilaxis, consisting of Ceftriaxone 2 g b.i.d, was administered before procedure, and was continued for 14 days, if the urinary infection was confirmed by a positive culture of urine. Pyelonephritis in pregnancy was treated with either intravenous Amoxicillin Amoxicillin 1 g q.d.s plus Gentamicin 5 mg/kg/day for 14 days or Ceftriaxone 2 g b.i.d. Urosepsis cases were evaluated in the intensive care unit, and received Ceftriaxone 2 g b.i.d, Piperacillin/tazobactam 4.5 g t.i.d or Meropenem 1 g t.i.d (for multiresistant bacteria), along with supportive treatment.
Ureterohydronephrosis, whether simple (n = 37; 71.2%) or infected (n = 13; 25%), was the main indication for double-J ureteric stenting in our cohort of patients. The right side was the most affected, and bilateral occurrence of the simple UHN was encountered in three cases (5.8%), while bilateral infected UHN manifested in two cases. (3.8%)
The mean duration of the procedure was 28.32 ± 13.4 min. Double-J ureteric stent insertion was performed in 46 cases (88.4%), while in six cases (11.6%) double-J stents were replaced because they were in place for at least 6 weeks. We used only local anesthesia for performing these procedures. The mean duration of the hospitalization in the Urology Department was 5.19 ± 1.98 days.
In two cases, additional procedures were required. In one case, retrograde ureteroscopy with lithotripsy (n = 1; 1.92%) was performed for a pelvic ureteral calculus, followed by double-J stent insertion. Because a wire could not be passed through the cystoscope and the obstructive calculus was smaller than 10 mm in diameter, we performed retrograde ureteroscopy with lithotripsy. In another case, due to significant calcification of the distal end of the double- stent, endoscopic lithotripsy (n = 1; 1.92%) was performed in order to retrieve the stent for replacement. Intravenous general anesthesia without oro-tracheal intubation was performed in these two cases.
A total of 21 patients (40.3%) reported pain or urinary discomfort after the procedure, and we administered intravenous Acetaminophen 1 g b.i.d, Metamizole 1 g b.i.d or Drotaverine hydrochloride 40 mg b.i.d. Stent migration (n = 3; 5.76%) or encrustation (n = 2; 3.84%), as well as reflux pyelonephritis (n = 2; 3.84%) and gross hematuria (n = 1; 1.92%) were other complications recorded during follow-up. No maternal or fetal death was recorded following the procedure.

4. Discussion

In this retrospective study, we assessed the safety and effectiveness of double-J ureteric stenting in pregnant women with ureterohydronephrosis, renal obstruction due to calculi or physiological ureteral obstruction, and their infectious complications, as well as the pregnancy outcomes of this cohort of patients in comparison with a control group.
Our results showed that the double-J stenting is a safe and effective treatment option for pregnant patients. Most of the procedures were performed during the second trimester. It was reported that double-J ureteric stenting can be difficult in the third trimester due to the tortuosity of the ureter [24]. However, we did not confirm this aspect because all our patients had successful stenting, regardless of the trimester of pregnancy.
The main indication for these procedures was UHN, simple (71.2%) or complicated with infection (25%). Right ureterohydronephrosis was the most frequently encountered in our cohort of patients. This aspect can be explained by the dextrorotation of the uterus during pregnancy with subsequent vascular compression, and by the anatomical relationship of the ureter with iliac and ovarian vessels [25,26]. All patients had complete resolution of the hydronephrosis on follow-up renal ultrasound and regression of hydronephrosis and urinary symptoms after ureteral stenting.
Escherichia coli, Klebsiella spp., and Enterococcus spp. were the main determinants of infectious complications in our cohort of patients. This bacterial spectrum corresponds to the pathogenic microorganisms associated with UTI in pregnancy [27,28,29]. All patients underwent antibioprophilaxis with a third-generation cephalosporin, Ceftriaxone, which was continued for 14 days if an UTI was confirmed by urine culture.
Complicated UTIs such as pyelonephritis were treated with either a combination of intravenous Amoxicillin plus Gentamicin or Ceftriaxone for two weeks. The use of an aminoglycoside was considered after weighting the risks and benefits of this drug during pregnancy, and all patients agreed with its administration after a proper counseling. Current literature data, although limited, does not support an association between Gentamicin use and increased risk of birth defects or audiologic deficits [30,31,32].
In the case of urosepsis, supplementary antibiotic options included Piperacillin/tazobactam and Meropenem along with supportive treatment, as recommended by current guidelines [23,33]. Meropenem was reserved for the treatment of severe infections caused by extended-spectrum β-lactamases (ESBL) positive Escherichia coli.
The mean duration of the procedure was 28.32 ± 13.4 min. Unilateral placement of the double-J ureteric stent was performed in the majority of cases (n = 46; 88.4%), and in 12 cases (23%) double-J stents were replaced because they were in place for at least 6 weeks. The mean duration of the hospitalization was 5.19 ± 1.98 days. We must emphasize that all procedures of double-J insertion were made in an emergency regime due to the known fact that lumbar pain secondary to physiologic ureteral obstruction, symptomatic lithiasis, and ascending urinary infections carry a higher risk for poor maternal and fetal outcomes [34,35,36]. We preferred to rapidly solve the urinary stasis and avoid the prolonged conservative approach reported in other studies [37,38,39]. Furthermore, we postponed ureteroscopy or percutaneous nephrolithotomy until after birth.
In two cases, additional procedures were required. Retrograde ureteroscopy with lithotripsy was performed for a pelvic ureteral calculus, followed by double-J stent insertion. Due to significant calcification of the distal end of the double-J stent, endoscopic lithotripsy was performed for another case in order to retrieve the stent for replacement. In our study, we replaced 12 double-J stents that were placed for more than 6 weeks. It has been reported that if a double-J stent is indwelled for 6 weeks, 6–12 weeks, or greater than 12 weeks, the rates of stent encrustation are 9.2 percent, 47.5 percent, and 76.3 percent, respectively [40]. The general opinion is that within 6 weeks to 6 months, the stent should be replaced or removed [40,41,42]. After birth, the stents were removed, and we performed a urography to identify calculi.
In our cohort of patients, the complication rates were low, and no fetal or maternal morbidity was recorded. Similar rates of stent migration, stent encrustation, reflux pyelonephritis, and hematuria were reported in other series of pregnant patients [15,43].
As for pregnancy outcomes, it appeared that the cesarean rate was significantly higher in the interventional group compared to the control group (34.8% vs. 24.3%), and the Apgar score at birth appeared to be significantly lower in the interventional group (8.02 ± 1.56 vs. 8.73 ± 1.24).
Preterm labour, as well as premature rupture of membrane rates, were significantly higher in the interventional group. Tocolysis included calcium channel blockers (Nifedipine), magnesium sulphate (also used for neuroprotection) or betamimetics (Hexoprenaline). The results from the univariate analysis showed that preterm birth rates, as well as NICU admission rates, were significantly higher in the interventional group. However, the propensity score match analysis did not support the higher NICU admission rates in the control group. No neonatal death was recorded. Similar findings were outlined in pregnant patients with a urologic pathology [44,45].
Postpartum UTIs were more frequently encountered in the interventional group, and the bacterial spectrum responsible for postpartum UTIs was similar to that described in the pre-procedural urine culture, with Escherichia coli, Klebsiella spp., and Enterococcus spp. being the most prevalent. The higher risk of postpartum urinary infection can be explained by the presence of double-J stents, which increase this risk, and by low patient compliance, persistent infections, or reinfections.
The main limitation of our study was that we could not include the majority of pregnant patients operated on at ‘Parhon Hospital’ during the selected period due to the lack of data about obstetrical outcomes. Other limitations included the retrospective and unicentric study design. A greater cohort of patients recruited from multiple centers would allow a more comprehensive picture of the issue.

5. Conclusions

In this study, we provided consistent data that support our approach of urologic emergencies during pregnancy. Double-J stenting is a safe and effective procedure that can be easily performed throughout pregnancy using only local anesthesia.
Further research is needed to evaluate larger cohorts of patients with various poor obstetrical outcomes possibly associated with the double-J ureteric stenting procedure.

Author Contributions

Conceptualization, V.D.R. and I.-A.V.; methodology, D.S., R.-C.C., V.G., V.N. and I.-A.V.; formal analysis, V.D.R., L.B., D.N., A.C. and I.-S.S.; investigation, P.O.; data curation, V.N. and V.G.; writing, original draft preparation, V.D.R., I.-A.V. and D.S.; writing, review and editing, V.D.R. and I.-A.V.; supervision, D.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of Ethical approval for this study was obtained from the Institutional Ethics Committees of ‘Cuza-Voda’ Maternity Hospital (No. 2871/05.03.2022) and ‘C.I. Parhon’ University Hospital (No. 1808/04.03.2022).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to local policies.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Faúndes, A.; Brícola-Filho, M.; Pinto e Silva, J.L. Dilatation of the urinary tract during pregnancy: Proposal of a curve of maximal caliceal diameter by gestational age. Am. J. Obstet. Gynecol. 1998, 178, 1082–1086. [Google Scholar] [CrossRef]
  2. Schulman, A.; Herlinger, H. Urinary tract dilatation in pregnancy. Br. J. Radiol. 1975, 48, 638–645. [Google Scholar] [CrossRef] [PubMed]
  3. Connolly, A.; Thorp, J.M. Urinary Tract Infections in Pregnancy. Urol. Clin. N. Am. 1999, 26, 779–787. [Google Scholar] [CrossRef]
  4. Semins, M.J.; Matlaga, B.R. Kidney stones during pregnancy. Nat. Rev. Urol. 2014, 11, 163–168. [Google Scholar] [CrossRef] [PubMed]
  5. Zhou, Q.; Chen, W.Q.; Xie, X.S.; Xiang, S.L.; Yang, H.; Chen, J.H. Maternal and neonatal outcomes of pregnancy complicated by urolithiasis: A systematic review and meta-analysis. J. Nephrol. 2021, 34, 1569–1580. [Google Scholar] [CrossRef] [PubMed]
  6. D’Elia, F.L.; Brennan, R.E.; Brownstein, P.K. Acute renal failure secondary to ureteral obstruction by a gravid uterus. J. Urol. 1982, 128, 803–804. [Google Scholar] [CrossRef]
  7. vanSonnenberg, E.; Casola, G.; Talner, L.B.; Wittich, G.R.; Varney, R.R.; D’Agostino, H.B. Symptomatic renal obstruction or urosepsis during pregnancy: Treatment by sonographically guided percutaneous nephrostomy. AJR Am. J. Roentgenol. 1992, 158, 91–94. [Google Scholar] [CrossRef] [Green Version]
  8. Liu, Y.; Ma, X.; Zheng, J.; Liu, X.; Yan, T. Pregnancy outcomes in patients with acute kidney injury during pregnancy: A systematic review and meta-analysis. BMC Pregnancy Childbirth 2017, 17, 235. [Google Scholar] [CrossRef] [Green Version]
  9. Krajewski, W.; Wojciechowska, J.; Dembowski, J.; Zdrojowy, R.; Szydełko, T. Hydronephrosis in the course of ureteropelvic junction obstruction: An underestimated problem? Current opinions on the pathogenesis, diagnosis and treatment. Adv. Clin. Exp. Med. 2017, 26, 857–864. [Google Scholar] [CrossRef] [Green Version]
  10. Mervak, B.M.; Altun, E.; McGinty, K.A.; Hyslop, W.B.; Semelka, R.C.; Burke, L.M. MRI in pregnancy: Indications and practical considerations. J. Magn. Reson. Imaging 2019, 49, 621–631. [Google Scholar] [CrossRef]
  11. Shrotri, K.N.; Morrison, I.D.; Shrotri, N.C. Urological conditions in pregnancy: A diagnostic and therapeutic challenge. J. Obstet. Gynaecol. 2007, 27, 648–654. [Google Scholar] [CrossRef] [PubMed]
  12. Demir, M.; Yagmur, İ.; Pelit, E.S.; Katı, B.; Ördek, E.; Çiftçi, H. Urolithiasis and Its Treatment in Pregnant Women: 10-Year Clinical Experience from a Single Centre. Cureus 2021, 13, e13752. [Google Scholar] [CrossRef] [PubMed]
  13. González-Padilla, D.A.; González-Díaz, A.; García-Rojo, E.; Abad-López, P.; Santos-Pérez de la Blanca, R.; Hernández-Arroyo, M.; Teigell-Tobar, J.; Peña-Vallejo, H.; Rodríguez-Antolín, A.; Cabrera-Meirás, F. Analgesic refractory colic pain: Is prolonged conservative management appropriate? Am. J. Emerg. Med. 2021, 44, 137–142. [Google Scholar] [CrossRef] [PubMed]
  14. Cheriachan, D.; Arianayagam, M.; Rashid, P. Symptomatic urinary stone disease in pregnancy. Aust. N. Z. J. Obstet. Gynaecol. 2008, 48, 34–39. [Google Scholar] [CrossRef] [PubMed]
  15. Ngai, H.Y.; Salih, H.Q.; Albeer, A.; Aghaways, I.; Buchholz, N. Double-J ureteric stenting in pregnancy: A single-centre experience from Iraq. Arab. J. Urol. 2013, 11, 148–151. [Google Scholar] [CrossRef]
  16. Apgar, V. A proposal for a new method of evaluation of the newborn infant. Curr. Res. Anesth. Analg. 1953, 32, 260–267. [Google Scholar] [CrossRef]
  17. Apgar, V.; Holaday, D.A.; James, L.S.; Weisbrot, I.M.; Berrien, C. Evaluation of the newborn infant; second report. J. Am. Med. Assoc. 1958, 168, 1985–1988. [Google Scholar] [CrossRef]
  18. Salomon, L.J.; Alfirevic, Z.; Bilardo, C.M.; Chalouhi, G.E.; Ghi, T.; Kagan, K.O.; Lau, T.K.; Papageorghiou, A.T.; Raine-Fenning, N.J.; Stirnemann, J.; et al. ISUOG practice guidelines: Performance of first-trimester fetal ultrasound scan. Ultrasound Obs. Gynecol. 2013, 41, 102–113. [Google Scholar] [CrossRef]
  19. Onen, A. Grading of Hydronephrosis: An Ongoing Challenge. Front. Pediatr. 2020, 8, 458. [Google Scholar] [CrossRef]
  20. Szkodziak, P. Ultrasound screening for pyelectasis in pregnant women. Clinical necessity or “art for art’s sake”? J. Ultrason. 2018, 18, 152–157. [Google Scholar] [CrossRef]
  21. Colgan, R.; Williams, M.; Johnson, J.R. Diagnosis and treatment of acute pyelonephritis in women. Am. Fam. Physician 2011, 84, 519–526. [Google Scholar] [PubMed]
  22. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 801–810. [Google Scholar] [CrossRef] [PubMed]
  23. Urology, E.A.O. EAU Guidelines; Edn. Presented at the EAU Annual Congress Amsterdam, The Netherlands; EAU Guidelines Office: Arnhem, The Netherlands, 2022; ISBN 978-94-92671-16-5. [Google Scholar]
  24. Drago, J.R.; Rohner, T.J., Jr.; Chez, R.A. Management of urinary calculi in pregnancy. Urology 1982, 20, 578–581. [Google Scholar] [CrossRef]
  25. Stothers, L.; Lee, L.M. Renal colic in pregnancy. J. Urol. 1992, 148, 1383–1387. [Google Scholar] [CrossRef]
  26. Vendola, N.; Giumelli, P.; Galdini, R.; Bennici, S. Ureteral drainage with double-J catheters in obstructive uropathy during pregnancy. A report of 3 cases. Gynecol. Obstet. Investig. 1995, 40, 274–275. [Google Scholar] [CrossRef] [PubMed]
  27. Sheiner, E.; Mazor-Drey, E.; Levy, A. Asymptomatic bacteriuria during pregnancy. J. Matern. Fetal. Neonatal. Med. 2009, 22, 423–427. [Google Scholar] [CrossRef]
  28. Balachandran, L.; Jacob, L.; Al Awadhi, R.; Yahya, L.O.; Catroon, K.M.; Soundararajan, L.P.; Wani, S.; Alabadla, S.; Hussein, Y.A. Urinary Tract Infection in Pregnancy and Its Effects on Maternal and Perinatal Outcome: A Retrospective Study. Cureus 2022, 14, e21500. [Google Scholar] [CrossRef]
  29. Geerlings, S.E. Clinical Presentations and Epidemiology of Urinary Tract Infections. Microbiol. Spectr. 2016, 4, 4–5. [Google Scholar] [CrossRef] [Green Version]
  30. Kirkwood, A.; Harris, C.; Timar, N.; Koren, G. Is gentamicin ototoxic to the fetus? J. Obstet. Gynaecol. Can. 2007, 29, 140–145. [Google Scholar] [CrossRef]
  31. Leung, J.C.; Cifra, C.L.; Agthe, A.G.; Sun, C.-C.J.; Viscardi, R.M. Antenatal factors modulate hearing screen failure risk in preterm infants. Arch. Dis. Child.-Fetal Neonatal Ed. 2016, 101, 56–61. [Google Scholar] [CrossRef]
  32. Czeizel, A.E.; Rockenbauer, M.; Olsen, J.; Sørensen, H.T. A teratological study of aminoglycoside antibiotic treatment during pregnancy. Scand. J. Infect. Dis. 2000, 32, 309–313. [Google Scholar] [PubMed]
  33. Napolitano, L.M. Sepsis 2018: Definitions and Guideline Changes. Surg. Infect. 2018, 19, 117–125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Ciciu, E.; Paṣatu-Cornea, A.-M.; Petcu, L.C.; Tuţă, L.-A. Early diagnosis and management of maternal ureterohydronephrosis during pregnancy. Exp. Ther. Med. 2022, 23, 1–6. [Google Scholar] [CrossRef] [PubMed]
  35. Korkes, F.; Rauen, E.C.; Heilberg, I.P. Urolithiasis and pregnancy. J. Bras. Nefrol. 2014, 36, 389–395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Szweda, H.; Jóźwik, M. Urinary tract infections during pregnancy—An updated overview. Dev. Period Med. 2016, 20, 263–272. [Google Scholar] [PubMed]
  37. Parulkar, B.; Hopkins, T.; Wollin, M.; Howard, P.; Lal, A. Renal colic during pregnancy: A case for conservative treatment. J. Urol. 1998, 159, 365–368. [Google Scholar] [CrossRef]
  38. Blanco, L.T.; Socarras, M.R.; Montero, R.F.; Diez, E.L.; Calvo, A.O.; Gregorio, S.A.; Cansino, J.R.; Galan, J.A.; Rivas, J.G. Renal colic during pregnancy: Diagnostic and therapeutic aspects. Literature review. Cent. Eur. J. Urol. 2017, 70, 93. [Google Scholar]
  39. Andreoiu, M.; MacMahon, R. Renal colic in pregnancy: Lithiasis or physiological hydronephrosis? Urology 2009, 74, 757–761. [Google Scholar] [CrossRef]
  40. Bultitude, M.F.; Tiptaft, R.C.; Glass, J.M.; Dasgupta, P. Management of encrusted ureteral stents impacted in upper tract. Urology 2003, 62, 622–626. [Google Scholar] [CrossRef]
  41. Borboroglu, P.G.; Kane, C.J. Current management of severely encrusted ureteral stents with a large associated stone burden. J. Urol. 2000, 164, 648–650. [Google Scholar] [CrossRef]
  42. Kawahara, T.; Ito, H.; Terao, H.; Yamagishi, T.; Ogawa, T.; Uemura, H.; Kubota, Y.; Matsuzaki, J. Ureteral stent retrieval using the crochet hook technique in females. PLoS ONE 2012, 7, e29292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Delakas, D.; Karyotis, I.; Loumbakis, P.; Daskalopoulos, G.; Kazanis, J.; Cranidis, A. Ureteral drainage by double-J-catheters during pregnancy. Clin. Exp. Obstet. Gynecol. 2000, 27, 200–202. [Google Scholar] [PubMed]
  44. Ordon, M.; Dirk, J.; Slater, J.; Kroft, J.; Dixon, S.; Welk, B. Incidence, Treatment, and Implications of Kidney Stones During Pregnancy: A Matched Population-Based Cohort Study. J. Endourol. 2020, 34, 215–221. [Google Scholar] [CrossRef] [PubMed]
  45. Lewis, D.F.; Robichaux, A.G., 3rd; Jaekle, R.K.; Marcum, N.G.; Stedman, C.M. Urolithiasis in pregnancy. Diagnosis, management and pregnancy outcome. J. Reprod. Med. 2003, 48, 28–32. [Google Scholar] [CrossRef] [PubMed]
Table
Table 1. Demographic characteristics, comorbidities, and pregnancy outcomes of the evaluated groups.
Table 1. Demographic characteristics, comorbidities, and pregnancy outcomes of the evaluated groups.
VariableWithout Double-J Stent (63 Patients) With Double-J Stent (52 Patients)p Value
Demographic characteristicsAge28.7 ± 5.7526.12 ± 5.740.018
Number of gestations2.25 ± 1.452.40 ± 2.130.65
Parity 1.87 ± 1.282.02 ± 1.870.62
ComorbiditiesPrevious cesarean section No 53 (46.1%)
Yes 10 (8.7%)		No 44 (38.3%)
Yes 8 (7%)		0.94
Placenta praeviaNo 58 (50.4%)
Yes 5 (4.3%)		No 48 (41.7%)
Yes 4 (3.5%)		0.96
Gestational hypertensionNo 57 (49.6%)
Yes 6 (5.2%)		No 50 (43.5%)
Yes 2 (1.7%)		0.23
PreeclampsiaNo 62 (53.9%)
Yes 1 (0.8%)		No 49 (42.6%)
Yes 3 (2.6%)		0.22
Previous renal colicNo 61 (53%)
Yes 2 (1.7%)		No 42 (36.5%)
Yes 10 (8.6%)		0.005
Previous nephrolithiasisNo 62 (53.9%)
Yes 1 (0.8%)		No 43 (37.3%)
Yes 9 (7.8%)		0.002
In vitro fertilizationNo 62 (53.9%)
Yes 1 (0.9%)		No 51 (44.3%)
Yes 1 (0.9%)		0.89
Pregnancy outcomesType of birthCesarean 28 (24.3%)
Vaginal 35 (30.4%)		Cesarean 40 (34.8%)
Vaginal 12 (10.4%)		<0.001
Newborn’s genderFemale 31 (27%)
Male 32 (27.8%)		Female 26 (22.6%)
Male 26 (22.6%)		0.93
Apgar score8.73 ± 1.248.02 ± 1.560.007
Preterm labourNo 54 (46.9%)
Yes 9 (7.8%)		No 36 (31.3%)
Yes 16 (13.9%)		0.03
Premature rupture of membranesNo 62 (53%)
Yes 1 (1.7%)		No 44 (33%)
Yes 8 (12.1%)		0.006
Preterm birthNo 61 (53%)
Yes 2 (1.7%)		No 38 (33%)
Yes 14 (12.1%)		0.002
Fetal growth restrictionNo 61 (53%)
Yes 2 (1.7%)		No 47 (40.8%)
Yes 5 (4.3%)		0.15
PreeclampsiaNo 62 (53.9%)
Yes 1 (0.9%)		No 51 (44.3%)
Yes 1 (0.9%)		0.89
NICU admissionNo 59 (51.3%)
Yes 4 (3.4%)		No 42 (36.5%)
Yes 10 (8.6%)		0.03
Fetal death0 (0%)
Post-partum UTINo 61 (53%)
Yes 2 (1.7%)		No 40 (34.8%)
Yes 12 (10.4%)		<0.001
Table
Table 2. Results from the propensity score match analysis.
Table 2. Results from the propensity score match analysis.
OutcomeRobust Standard Error (RSE)Coefficient95% Confidence Intervalp Value
Lower LimitUpper Limit
Type of birth (cesarean)0.0890.3620.1860.538<0.001
Preterm labour0.0910.160−0.0180.3400.039
Premature rupture of membranes0.0550.105−0.0020.2140.026
Preterm birth0.0750.2360.0870.3840.002
Fetal growth restriction0.0500.056−0.0410.150.26
Preeclampsia0.018−0.008−0.0440.0270.63
NICU admission0.0640.086−0.0390.2130.17
Post-partum UTI0.0660.1660.0360.2960.012
Table
Table 3. Summary of double-J ureteric stenting.
Table 3. Summary of double-J ureteric stenting.
VariableMean (±SD) or n (%)
Timing of the procedure (weeks of gestation/trimester of pregnancy)Mean (SD) 23.21 ± 7.11
First trimester 5 (9.6%)
Second trimester 29 (55.8%)
Third trimester 18 (34.6%)
LeukocytosisPre-procedure 15,345.23 ± 2340.4/mm3
Post-procedure 8650.8 ± 1890.3/mm3
CRPPre-procedure 123.32 ± 46 mg/l
Urinalysis and urine cultureLeukocyturia 31 (59.6%)
Escherichia coli 19 (36.5%)
Klebsiella spp. 5 (9.61%)
Enterococcus spp. 4 (7.6%)
Serratia spp. 2 (3.8%)
Staphylococcus spp. 1 (1.92%)
Indications for double-J stenting Simple UHN 37 (71.2%)
Simple UHN location:
  • Left 11 (21.2%)
  • Right 23 (44.2%)
  • Bilateral 3 (5.8%)
Infected UHN 13 (25%)
Infected UHN location:
  • Left 1 (1.9%)
  • Right 10 (19.2%)
  • Bilateral 2 (3.8%)
UHN grade 1.67 ± 0.51
Urolithiasis 14 (26.9%)
Urolithiasis location:
  • Left 5 (9.6%)
  • Right 8 (15.4%)
  • Bilateral 1 (1.9%)
Urosepsis 15 (28.8%)
Pyelonephritis 3 (5.7%)
Pyelonephritis location:
  • Left 1 (1.9%)
  • Right 2 (3.8%)
Types of interventionsDouble-J ureteric stent insertion n = 46 (88.4%)
Double-J ureteric stent replacement n = 6 (11.6%)
Associated proceduresRetrograde ureteroscopy with lithotripsy 1 (1.92%)
Endoscopic lithotripsy 1 (1.92%)
ComplicationsPain/ urinary discomfort 21 (40.3%)
Stent migration 3 (5.76%)
Stent encrustation 2 (3.84%)
Reflux pyelonephritis 2 (3.84%)
Gross hematuria 1 (1.92%)
Duration of hospitalization5.19 ± 1.98 days
Duration of the procedure 28.32 ± 13.4 min
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Radu, V.D.; Vasilache, I.-A.; Costache, R.-C.; Scripcariu, I.-S.; Nemescu, D.; Carauleanu, A.; Nechifor, V.; Groza, V.; Onofrei, P.; Boiculese, L.; et al. Pregnancy Outcomes in a Cohort of Patients Who Underwent Double-J Ureteric Stenting—A Single Center Experience. Medicina 2022, 58, 619. https://doi.org/10.3390/medicina58050619

AMA Style

Radu VD, Vasilache I-A, Costache R-C, Scripcariu I-S, Nemescu D, Carauleanu A, Nechifor V, Groza V, Onofrei P, Boiculese L, et al. Pregnancy Outcomes in a Cohort of Patients Who Underwent Double-J Ureteric Stenting—A Single Center Experience. Medicina. 2022; 58(5):619. https://doi.org/10.3390/medicina58050619

Chicago/Turabian Style

Radu, Viorel Dragos, Ingrid-Andrada Vasilache, Radu-Cristian Costache, Ioana-Sadiye Scripcariu, Dragos Nemescu, Alexandru Carauleanu, Valentin Nechifor, Veaceslav Groza, Pavel Onofrei, Lucian Boiculese, and et al. 2022. "Pregnancy Outcomes in a Cohort of Patients Who Underwent Double-J Ureteric Stenting—A Single Center Experience" Medicina 58, no. 5: 619. https://doi.org/10.3390/medicina58050619

Article Metrics

Back to TopTop